Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection

Antoine Bachelard,Quentin Le Hingrat,Valentine-Marie Ferré,Minh Lê,Gilles Peytavin,Florence Damond,Charlotte Charpentier,Guillemette Fremont Goudot,Jeanne Goupil de Bouille,Sylvie Lariven,Pierre Delobel,Yazdan Yazdanpanah,Diane Descamps,Sophie Matheron,Jade Ghosn,ANRS CO05 VIH-2 cohort study group,Victor Appay,Brigitte Autran,Amel Besseghir,Sandrine Couffin-Cardiergues,Chloé Birklé,Françoise Brun-Vezinet,Geneviève Chêne,Rémi Cheynier,Fidéline Collin,Serge Eholie,Didier Ekouvie,Catherine Faguard,Delphine Lebrasseur,Julie Longobardi,Lucie Marchand,Michaela Muller-Trutwin,Alexandra Ozanne,Ventzislava Petrov-Sanchez,Céline Roy,Asier Saez-Cirion,François Simon,Linda Wittkop,Marie Caroline Meyohas,Karine Lacombe,Dominique Salmon,Agathe Rami,Gilles Pialoux,Roland Tubiana,Pierrre De Truchis,Marie-Aude Khuong-Josses,Ouda Derradji,Didier Troisvallet,Julie Timsit,Anne-Sophie Lascaux,Vincent Jeantils,Olivier Bouchaud,Olivier Patey,Pauline Caraux-Paz,Cécile Goujard,Laurence Gérard,Emmanuel Mortier,Eric Froguel,Yves Welker,Vincent Daneluzzi,Philippe Genet,Annie Leprêtre,David Zucman,Gilles Force,Anne Coutellier-Simon,Jean Deleuze,Laurence Weiss,Valérie Garrait,Hélène Masson Colin,Laurent Blum,Pr Jean-Daniel Lelièvre,Anne Dulioust,Véronique Perrone,Christophe Billy,Cécile Winter,Isabelle Aupérin,Iram La Torre,Jean-Michel Molina,Patrick Brunet,Sylvia Lamy,Alain Devidas,Amélie Chabrol,Elisabeth Rouveix,Serge Kernbaum,Claudine Duvivier,Marie-Anne Bouldouyre,Loïc Bodard,Patrick Imbert,Christophe Rapp,François Boué,Agnès Uludag,Fabrice Chaix,Olivia Son,Jean-Paul Viard,Xavier Duval,Alix Greder Belan,Valérie Grégoire,Genviève Beck-Wirth,François Raffi,Christine Drobacheff,Catherine Chirouze,Thierry Allègre,Renaud Verdon,Isabelle Poizot-Martin,Corinne Daniel,Moise Machado,Anne-Lise Lecapitaine,Pr Bruno Marchou,Louis Bernard,Yasmine Debab,Pascale Leclercq,Joelle Julien,Jacques Moreau,Isabelle Ravaux,Cédric Arvieux,Christophe Michaud,Djamila Makhloufi,Gwenael Lemoal,Philippe Arsac,Thierry Prazuck,Alain Lafeuillade,Benoit Martha,Philippe Perré,Faiza Ajana,Philippe Morlat,Elisabeth Brottier,Michel Dupon,Didier Neau,Jean-Luc Pellegrin,Isabelle Raymond,Nathalie Montagne,Thierry May,Heidi Wille,Youssef Douadi,Jacques Reynes,Jean-Louis Schmit,Chrisitne Rouger,Jean-Luc Berger,Yves Poinsignon,Christiane Jacomet,Lionel Piroth,Eric Rosenthal,Daniel Garipuy,Martin Michaud,Agnes Riché,François Prevoteau du Clary,Alica Naqvi,Jacques Gaillat,David Rey,François Abino,Patrick Mercié,Pierre-Marie Roger,Emmanuelle Aïssi,Jean-Marie Chennebault,Dominique Liné,Narimamy Randrianasolo,Catherine Merle,Patricia Granet,Laurence Caunègre,Laurent Cotte,Laurent Boileau,Jean-Batiste Euzen,Pascale Perfezou,Nicolas Lefebvre,Jean-Philippe Talarmin,Simona Pavel,Bénédicte Ponceau,Julien Saison,Albert Sotto,Didier Laureillard,Anne Vandendriessche,Iuliana Darasteanu,Manal Mecheri,Tounes Saidi,Ami Sangaré,Nathalie Chaghil-Boissière,Valérie Conte,Mohamed Dembelé,Youssra Khalil,Maxime Pallier,Loretxu Pinoges,Solaya Chalal,Lynda Oualit,Leia Becam,Sophie Cirscota,Carine Lascoux,Lydia Leger,Marie LeGoff,Isabelle Pellegrin,Leen Youssef,Françoise Brun-Vézinet,Gianfranco Pancino,Anne Hosmalin,Vincent Vieillard
DOI: https://doi.org/10.1093/cid/ciad695
2024-04-10
Abstract:We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
What problem does this paper attempt to address?